Carregando...
Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
Multiple myeloma (MM) remains an incurable disease regardless of recent advances in the field. Therefore, a substantial unmet need exists to treat patients with relapsed/refractory myeloma. The use of novel agents such as daratumumab, elotuzumab, carfilzomib, or pomalidomide, among others, usually c...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Principais autores: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7290012/ https://ncbi.nlm.nih.gov/pubmed/32582204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.01128 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|